Value202320242025TTMSelling/general/admin expenses336.6 M560.7 M456.4 M456.4 MResearch & development————Operating income63.1 M161.9 M872.6 M872.6 MNon-Operating Income, Total8.1 M32.2 M35.1 M35.1 MInterest expense, net of interest capitalized69.8 M———Non-Operating Income, excl. Interest Expenses-68.6 M10.9 M27.2 M27.2 MUnusual income/expense6.9 M21.3 M7.9 M7.9 MPretax income1.1 M275 M983 M983 MEquity in earnings————Taxes4.5 M3.5 M3.2 M3.2 MNon-controlling/minority interest————After tax other income/expense1 M9.3 M4.5 M4.5 MNet income before discontinued operations3.4 M271.5 M986.2 M986.2 MDiscontinued operations—57 M00Net income3.4 M328.5 M986.2 M986.2 MDilution adjustment————Preferred dividends————Diluted net income available to common stockholders3.4 M328.5 M986.2 M986.2 MBasic earnings per share (Basic EPS)-0.04-3.67-10.81-10.81Diluted earnings per share (Diluted EPS)-0.04-3.67-10.81-10.81Average basic shares outstanding88.8 M89.5 M——Diluted shares outstanding88.8 M89.5 M——EBITDA164.3 M441.8 M-405 M-822.7 MEBIT67.9 M354.9 M-483 M-900.7 MCost of revenue2.59 B2.16 B2.22 B2.22 BOther cost of goods sold2.59 B2.16 B2.22 B2.22 BDepreciation & amortization (cash flow)96.4 M86.9 M78 M78 M
Fortrea Holdings Inc
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.